Compare Incyte Corporation (INCY) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Incyte Corporation trades at $118.01 (market cap $23.11B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.91. The key difference: Incyte Corporation is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals.
| INCY | SJNK | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Sector/Thematic |
52-Week High | $118.52 | $25.63 |
52-Week Low | $67.38 | $24.75 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
SJNK trades at $24.92 with no price change in the last 24 hours, showing technical bearish signals from moving averages while oscillators remain neutral. The ETF maintains consistent dividend payments with recent distributions of $0.14-$0.15 per share. Current technical analysis indicates bearish momentum with key support and resistance clustered around $25 levels.
The short-term high-yield bond ETF faces headwinds from potential yield normalization after benefiting from falling rates. Analyst sentiment appears cautious with recent bearish ratings citing exhausted tailwinds. Key risks include interest rate sensitivity and credit spread volatility in the junk bond market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
